Intravitreal Administration of rhNGF Enhances Regenerative Processes in a Zebrafish Model of Retinal Degeneration.
Müller glia cells
age-related macular degeneration (AMD)
nerve growth factor (NGF)
neuroprotection
retinal regeneration
retinitis pigmentosa (RP)
translational research
zebrafish
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
11
2021
accepted:
28
01
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Nerve growth factor (NGF) is the best characterized neurotrophin, and it is known to play an important role in ocular homeostasis. Here, we demonstrated the expression of NGF receptors in adult zebrafish retina and optimized a light-induced retina degeneration (LID) zebrafish model that mimics human cone-rod disorders, demonstrating that intravitreal (IV) administration of rhNGF can boost zebrafish retinal regeneration in this model. Adult zebrafish retinae exposed to 60 h of light irradiation (60 h LID) displayed evident reduction of outer nuclear layer (ONL) thickness and cell number with presence of apoptotic cells. Retinal histologic evaluation at different time points showed that IV therapeutic injection of rhNGF resulted in an increase of ONL thickness and cell number at late time points after damage (14 and 21 days post injury), ultimately accelerating retinal tissue recovery by driving retinal cell proliferation. At a molecular level, rhNGF activated the ERK1/2 pathway and enhanced the regenerative potential of Müller glia
Identifiants
pubmed: 35330834
doi: 10.3389/fphar.2022.822359
pii: 822359
pmc: PMC8940169
doi:
Types de publication
Journal Article
Langues
eng
Pagination
822359Informations de copyright
Copyright © 2022 Cocchiaro, Di Donato, Rubbini, Mastropasqua, Allegretti, Mantelli, Aramini and Brandolini.
Déclaration de conflit d'intérêts
The authors PC, MA, FM, AA, and LB are employees of Dompé farmaceutici s.p.a. The authors VD and DR are employees of ZeClinics SL, IGTP. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2016 Apr 20;6:24851
pubmed: 27094545
Clin Interv Aging. 2017 Aug 22;12:1313-1330
pubmed: 28860733
J Pharmacol Sci. 2016 Jul;131(3):215-8
pubmed: 27430989
Mol Neurobiol. 2019 Feb;56(2):1056-1069
pubmed: 29869196
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):270-281
pubmed: 28114588
J Biol Chem. 2001 Jun 22;276(25):23000-8
pubmed: 11278285
Int J Mol Sci. 2017 Jan 05;18(1):
pubmed: 28067793
J Neurosci. 2013 Apr 10;33(15):6524-39
pubmed: 23575850
Clin Exp Optom. 2004 Mar;87(2):65-80
pubmed: 15040773
Exp Eye Res. 2012 Apr;97(1):105-16
pubmed: 22425727
Dev Biol. 1995 Jun;169(2):745-58
pubmed: 7781913
PLoS One. 2012;7(4):e36243
pubmed: 22558402
PeerJ. 2018 Sep 20;6:e5646
pubmed: 30258730
Dev Neurobiol. 2008 Feb 15;68(3):392-408
pubmed: 18161852
Ophthalmologica. 2008;222(1):58-61
pubmed: 18097183
Dev Dyn. 2014 Dec;243(12):1591-605
pubmed: 25220904
Nat Cell Biol. 2010 Nov;12(11):1101-7
pubmed: 20935637
Exp Eye Res. 2016 Feb;143:98-109
pubmed: 26492821
Biomed Res Int. 2014;2014:759473
pubmed: 25250333
Prog Brain Res. 2012;201:171-81
pubmed: 23186714
Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1743-9
pubmed: 18751719
Eye (Lond). 2017 Jan;31(1):68-86
pubmed: 27612182
Prog Retin Eye Res. 2003 Sep;22(5):607-55
pubmed: 12892644
Exp Eye Res. 2009 Jun;88(6):1051-64
pubmed: 19450453
J Glaucoma. 2011 Feb;20(2):100-8
pubmed: 20436364
Invest Ophthalmol Vis Sci. 2013 Feb 27;54(2):1516-21
pubmed: 23404118
J Transl Med. 2012 Nov 29;10:239
pubmed: 23190582
J Comp Neurol. 2018 Apr 15;526(6):1057-1072
pubmed: 29322524
Curr Neuropharmacol. 2018;16(10):1455-1465
pubmed: 29651949
Dev Cell. 2012 Feb 14;22(2):334-47
pubmed: 22340497
Acta Ophthalmol. 2016 Dec;94(8):748-754
pubmed: 27350263
Curr Eye Res. 2017 Jul;42(7):1064-1068
pubmed: 28632034
PeerJ. 2020 Dec 22;8:e10479
pubmed: 33391871
Nature. 2018 Aug;560(7719):484-488
pubmed: 30111842
Curr Eye Res. 2007 Sep;32(9):765-72
pubmed: 17882709
PLoS One. 2013 Apr 30;8(4):e63207
pubmed: 23646199
J Comp Neurol. 2002 Sep 16;451(2):127-41
pubmed: 12209832
Pharm Res. 2019 Feb 25;36(4):58
pubmed: 30805711
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1193-200
pubmed: 16505058
Crit Care. 2016 Apr 19;20(1):110
pubmed: 27095501
Comp Biochem Physiol Pharmacol Toxicol Endocrinol. 1994 May;108(1):1-10
pubmed: 8061955
Brain Res. 1990 Jul 16;523(1):11-5
pubmed: 2169962
J Anat. 2019 Jul;235(1):167-179
pubmed: 30945286
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15858-63
pubmed: 21911394
PLoS One. 2015 Apr 21;10(4):e0124810
pubmed: 25897972
Exp Eye Res. 2008 Nov;87(5):433-44
pubmed: 18718467
Cytokine Growth Factor Rev. 2017 Apr;34:43-57
pubmed: 27964967
J Neurobiol. 2000 Sep 5;44(3):289-307
pubmed: 10942883
Development. 2013 Nov;140(22):4510-21
pubmed: 24154521
Ann Ist Super Sanita. 2009;45(4):439-42
pubmed: 20061666
Curr Opin Genet Dev. 2016 Oct;40:41-47
pubmed: 27281280